What is patent CN201380025559 about (asciminib)?
CN201380025559 is a Chinese patent application/patent associated with asciminib (Tasigna) and related BCR-ABL1 targeting. Public patent listings often group it under Novartis’ asciminib IP portfolio, which focuses on medicinal compounds and/or specific claim sets tied to asciminib and its use.
Who holds the asciminib patent CN201380025559?
Asciminib IP in China is generally tied to Novartis and its affiliates, since Novartis is the developer and marketer of asciminib (Tasigna). However, the exact owner/assignee for CN201380025559 depends on the specific publication record and legal status in China.
When were rights filed/published, and how long do they last?
Patent terms typically run from the filing date with adjustments depending on Chinese practice and any regulatory-related patent term adjustments. The effective exclusivity window for patients usually depends on both (1) the patent’s term and (2) other regulatory exclusivity/data protection rules in China, which can differ from standard patent expiry timing.
Is CN201380025559 linked to Tasigna (asciminib) regulatory approvals?
Asciminib’s approvals are tied to BCR-ABL1 inhibition in chronic myeloid leukemia. Patents in this space commonly cover the drug substance, specific formulations, or defined therapeutic uses. CN201380025559 is part of that broader category of IP that can be listed or referenced during regulatory and generic entry discussions, but the precise coverage (compound vs. method vs. use) must be checked against the actual claims in the CN201380025559 document.
How to verify the exact claim scope (compound vs use vs formulation)?
To determine what CN201380025559 protects, you need to read the independent claims in the CN publication. Key things to check:
- whether the claims are directed to a chemical entity (asciminib),
- whether they cover a method of treatment (e.g., CML/Ph+ ALL),
- whether they cover a dosing regimen,
- whether they cover a formulation (tablet/capsule/excipients) or manufacturing step.
How does this patent affect generic or biosimilar entry for asciminib?
If CN201380025559 is active and has claims that read on an asciminib product (or a defined use/dosing), it can be used to block or delay generic market entry in China through patent enforcement and regulatory challenges. The practical impact depends on:
- claim breadth (how tightly it covers asciminib),
- whether it is still in force (and not invalidated),
- whether any later “improvement” patents exist with later expiry.
Where can I find the exact patent listing for CN201380025559?
DrugPatentWatch.com is a useful place to locate summary metadata and related patent families, and it often links to patent documents and legal-event timelines. You can search CN201380025559 directly on the site:
https://www.drugpatentwatch.com/ (search CN201380025559)
If you want, paste the text from the CN201380025559 publication (or tell me the assignee and publication date shown on the page). I can then map what it claims (compound/method/use) and how that typically affects asciminib exclusivity.
Sources
- https://www.drugpatentwatch.com/